Epidemiology and Public Health
The broad purpose of the Epidemiology and Public Health research group is contributing to increase the available scientific evidence regarding preventive interventions, to promote health, and prevent morbidity and mortality from major diseases. Our group uses epidemiological methods to study etiology, surveillance, and efficacy of these interventions. We are primarily focused on epidemiology and prevention of infectious diseases, in both individual and population levels.
Main lines of research:
- Vaccines: This research line includes the organization, participation and collaboration in different clinical trials related to the evaluation of the immunogenicity, efficacy and safety of different vaccines (e.g. Herpes Zoster, Respiratory Syncytial Virus, Influenza, Covid-19).
- The epidemiology and prevention of healthcare acquired infections: This research line includes the evaluation of risk factors, characteristics, evolution, host, and impact of these infections.
- Clinical Epidemiology of Multiple Sclerosis: The objective of this project is to characterize the epidemiology of Multiple Sclerosis in Catalonia.
Publications
Cellular and humoral immunogenicity of the mRNA-1273 SARS-CoV-2 vaccine in patients with hematologic malignancies.
PMID: 34844263
Journal: Blood Advances
Year: 2022
Reference: Blood Adv. 2022 Feb 8;6(3):774-784. doi: 10.1182/bloodadvances.2021006101.
Impact factor:
Publication type: Paper in international publication
Authors: Abrisqueta, Pau; Barba, Pere; Bosch, Francesc; Cabirta, Alba; Campins, Magda; Catala, Eva; Crespo, Marta; Esperalba, Juliana; Fernandez-Naval, Candela; Fox, Maria Laura et al.
DOI: 10.1182/bloodadvances.2021006101
Menopause and multiple sclerosis: Influence on prognosis and role of disease-modifying drugs and hormonal replacement therapy.
PMID: 32856989
Journal: Multiple Sclerosis Journal
Year: 2022
Reference: Mult Scler. 2022 Feb;28(2):173-182. doi: 10.1177/1352458520952022. Epub 2020 Aug 28.
Impact factor:
Publication type: Paper in international publication
Authors: Baro, Francesc; Midaglia, Luciana; Montalban, Xavier; Otero, Susana; Tintore, Mar et al.
DOI: 10.1177/1352458520952022
Persistent reduction of retinal microvascular vessel density in patients with moderate and severe COVID-19 disease.
PMID: 35039796
Journal: BMJ open ophthalmology
Year: 2022
Reference: BMJ Open Ophthalmol. 2022 Jan 11;7(1):e000867. doi: 10.1136/bmjophth-2021-000867. eCollection 2022.
Impact factor:
Publication type: Paper in international publication
Authors: Aragon, David; Azarfane, Brahim; Banderas Garcia, Sandra; Garcia-Arumi, Jose; Garrell-Salat, Xavier; Otero-Romero, Susana; Sanchez-Montalva, Adrian; Trejo, Fernando; Zapata, Miguel Angel et al.
DOI: 10.1136/bmjophth-2021-000867
Impact of COVID-19 pandemic on frequency of clinical visits, performance of MRI studies, and therapeutic choices in a multiple sclerosis referral centre.
PMID: 35001198
Journal: JOURNAL OF NEUROLOGY
Year: 2022
Reference: J Neurol. 2022 Apr;269(4):1764-1772. doi: 10.1007/s00415-021-10958-z. Epub 2022 Jan 10.
Impact factor:
Publication type: Paper in international publication
Authors: Arrambide, Georgina; Auger, Cristina; Carbonell, Pere; Cardenas-Robledo, Simon; Castillo, Joaquin; Castillo, Mireia; Cobo-Calvo, Alvaro; Comabella, Manuel; Espejo, Carmen; Galan, Ingrid et al.
DOI: 10.1007/s00415-021-10958-z
Nosocomial COVID-19. Prospective study in a referral hospital.
PMID: 34384612
Journal: MEDICINA CLINICA
Year: 2021
Reference: Med Clin (Barc). 2021 Jul 26. pii: S0025-7753(21)00433-4. doi: 10.1016/j.medcli.2021.07.005.
Impact factor: 1.725
Publication type: Letter whit IF
Authors: Escola-Verge, Laura, Borras-Bermejo, Blanca, Los-Arcos, Ibai, Esperalba, Juliana, Ferrer, Carmen, Fernandez-Hidalgo, Nuria et al.
DOI: 10.1016/j.medcli.2021.07.005
Epidemiological characteristics and outcomes of COVID-19 cases: mortality inequalities by socio-economic status, Barcelona, Spain, 24 February to 4 May 2020.
PMID: 34018483
Journal: Eurosurveillance
Year: 2021
Reference: Euro Surveill. 2021 May;26(20). doi: 10.2807/1560-7917.ES.2021.26.20.2001138.
Impact factor: 6.307
Publication type: Paper in international publication
Authors: Martin-Sanchez, Mario, Mercuriali, Lilas, Borras-Bermejo, Blanca, Lopez-Contreras, Joaquin, Vilella, Anna, Villar, Judit, Orcau, Angels, de Olalla, Patricia Garcia, Rius, Cristina, de Andres, Anna et al.
DOI: 10.2807/1560-7917.ES.2021.26.20.2001138
Influence of organization and demographic characteristics of primary care practices on continuity of care: analysis of a retrospective cohort from 287 primary care practices covering about 6 million people in Catalonia.
PMID: 33761874
Journal: BMC Family Practice
Year: 2021
Reference: BMC Fam Pract. 2021 Mar 25;22(1):56. doi: 10.1186/s12875-021-01414-y.
Impact factor: 2.497
Publication type: Paper in international publication
Authors: Coma, Ermengol, Mora, Nuria, Peremiquel-Trillas, Paula, Benitez, Mencia, Mendez, Leonardo, Mercade, Albert, Fina, Francesc, Fabregas, Mireia, Medina, Manuel et al.
DOI: 10.1186/s12875-021-01414-y
Prescription quality of prolonged antibiotherapy in pediatrics. Impact of ASP program interventions.
PMID: 32229130
Journal: ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA
Year: 2021
Reference: Enferm Infecc Microbiol Clin. 2021 Mar;39(3):134-138. doi: 10.1016/j.eimc.2020.02.015. Epub 2020 Mar 27.
Impact factor: 1.731
Publication type: Paper in national publication
Authors: Melendo, Susana, Fernandez-Polo, Aurora, Castellnou Asens, Ivette, Mendoza-Palomar, Natalia, Barnes-Mayolas, Meritxell, Soler-Palacin, Pere, Soler Palacin, Pere, Melendo Perez, Susana, Mendoza Palomar, Natalia, Nieves Larrosa Escartin, M et al.
DOI: 10.1016/j.eimc.2020.02.015
News
On European Antibiotic Awareness Day, we highlight the importance of using these medications responsibly and finding innovative solutions to combat this issue.
This strategy protects almost two thirds of patients. It also reduces the waiting time between vaccination and initiation of immune suppressive treatment.
L’Agència Europea de Medicaments autoritza la vacuna d'HIPRA contra la COVID-19 com a dosi de reforç
El VHIR va participar activament en l'assaig clínic d'aquesta vacuna que avaluava la seguretat, la tolerabilitat i l'eficàcia.